mbx-2982
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01035879)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Glucose-dependent insulinotropic receptor agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCc1cnc(N2CCC(c3nc(COc4ccc(-n5cnnn5)cc4)cs3)CC2)nc1- Mol. weight
- 448.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3260505 ↗
Also known as
- mbx-2982
- mbx-2982
- mbx-2982
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04432090 | Phase 2 | Oct 31, 2020 | Advent Health |
| NCT01035879 | Phase 2 | Dec 1, 2009 | CymaBay Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advent Health | Academic/Hospital | 1 | 1 | 1 | 2020 |
| CymaBay Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2009 |
2 organizations
Page 1 / 1